With Food and Drug Administration approval pending for two newMRI contrast agents, manufacturers are jockeying for legal footholdsin this potentially explosive market. Bristol-Myers Squibb (BMS) has already swapped marketing rightswith Schering AG to
With Food and Drug Administration approval pending for two newMRI contrast agents, manufacturers are jockeying for legal footholdsin this potentially explosive market.
Bristol-Myers Squibb (BMS) has already swapped marketing rightswith Schering AG to clear the way for Prohance, an experimentalnonionic gadolinium-based agent. Schering holds patents on gadolinium-basedimage enhancement technology.
Under the terms of the Squibb-Schering deal, Schering receivesU.S. marketing rights to Squibb's antiarrhythmic agent Betapace,said Janet Skidmore, BMS director of international public affairs.BMS receives worldwide rights under Schering's existing patentsand patent applications relating to gadolinium-based Prohance.
The drug received a favorable review by FDA commissioners lastNovember and BMS predicts FDA approval by the end of the year.
"We're very optimistic that we'll see approval of Prohancein 1992. But the FDA operates in its own time frame, so we don'tknow exactly when the word will come down," Skidmore said.
Also racing to the FDA finish line is Omniscan, another nonionicgadolinium agent, manufactured by Nycomed and licensed by SterlingWinthrop.
A Schering AG representative has discounted rumors that theGerman pharmaceutical company filed a patent infringement suitagainst Nycomed and Sterling Winthrop over Omniscan (SCAN 5/20/92).Schering holds patents on gadolinium-based image enhancement technology.
"Schering has not filed any such suit for patent infringementagainst Nycomed," said Wendy Neininger, Schering's pressliaison in New York. "The rumor is unfounded."
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.